Correlation between lipoprotein-associated phospholipase A2 and poststroke mild cognitive impairment

References

• Ikonomidis I, Michalakeas CA, Lekakis J, et al. The role of lipoprotein-associated phospholipase A2 (Lp-PLA₂) in cardiovascular disease. Rev Recent Clin Trials. 2011 May;6(2):108–113. doi: 10.2174/157488711795177903
   PubMedGoogle Scholar
• Cai A, Zheng D, Qiu R, et al. Lipoprotein-associated phospholipase A2 (Lp-PLA(2)): a novel and promising biomarker for cardiovascular risks assessment. Dis Markers. 2013;34(5):323–331. doi: 10.1155/2013/432136
   PubMed Web of Science ®Google Scholar
• Theilmeier G, De Geest B, Van Veldhoven PP, et al. HDL-associated PAF-AH reduces endothelial adhesiveness in apoE-/- mice. FASEB J. 2000 Oct;14(13):2032–2039. doi: 10.1096/fj.99-1029com
   PubMed Web of Science ®Google Scholar
• Wilensky RL, Shi Y, Mohler ER 3rd, et al. Inhibition of lipoprotein-associated phospholipase A2 reduces complex coronary atherosclerotic plaque development. Nat Med. 2008 Oct;14(10):1059–1066. doi: 10.1038/nm.1870
   PubMed Web of Science ®Google Scholar
• May HT, Horne BD, Anderson JL, et al. Lipoprotein-associated phospholipase A2 independently predicts the angiographic diagnosis of coronary artery disease and coronary death. Am Heart J. 2006 Nov;152(5):997–1003. doi: 10.1016/j.ahj.2006.01.011
   PubMed Web of Science ®Google Scholar
• Jenny NS, Solomon C, Cushman M, et al. Lipoprotein-associated phospholipase A(2) (Lp-PLA(2)) and risk of cardiovascular disease in older adults: results from the Cardiovascular Health Study. Atherosclerosis. 2010 Apr;209(2):528–532. doi: 10.1016/j.atherosclerosis.2009.09.021
   PubMed Web of Science ®Google Scholar
• Thompson A, Gao P, Orfei L, et al. Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies. Lancet. 2010May 1;375(9725):1536–1544. doi: 10.1016/S0140-6736(10)60319-4 PMID: 20435228; PMCID: PMC2864403.
   PubMed Web of Science ®Google Scholar
• Dohi T, Miyauchi K, Okazaki S, et al. Decreased circulating lipoprotein-associated phospholipase A2 levels are associated with coronary plaque regression in patients with acute coronary syndrome. Atherosclerosis. 2011 Dec;219(2):907–912. doi: 10.1016/j.atherosclerosis.2011.09.019
   PubMed Web of Science ®Google Scholar
• Anstey KJ, Lipnicki DM, Low LF. Cholesterol as a risk factor for dementia and cognitive decline: a systematic review of prospective studies with meta-analysis. Am J Geriatr Psychiatry. 2008 May;16(5):343–354. doi: 10.1097/01.JGP.0000310778.20870.ae
   PubMed Web of Science ®Google Scholar
• Kennelly SP, Lawlor BA, Kenny RA. Blood pressure and the risk for dementia: a double edged sword. Ageing Res Rev. 2009 Apr;8(2):61–70. doi: 10.1016/j.arr.2008.11.001
   PubMed Web of Science ®Google Scholar
• van Oijen M, van der Meer IM, Hofman A, et al. Lipoprotein-associated phospholipase A2 is associated with risk of dementia. Ann Neurol. 2006 Jan;59(1):139–144. doi: 10.1002/ana.20721
   PubMed Web of Science ®Google Scholar
• Fitzpatrick AL, Irizarry MC, Cushman M, et al. Lipoprotein-associated phospholipase A2 and risk of dementia in the cardiovascular health study. Atherosclerosis. 2014 Aug;235(2):384–391. doi: 10.1016/j.atherosclerosis.2014.04.032
   PubMed Web of Science ®Google Scholar
• Jiang R, Chen S, Shen Y, et al. Higher levels of lipoprotein associated phospholipase A2 is associated with increased prevalence of cognitive impairment: the APAC study. Sci Rep. 2016 Sep 9;6(1):33073. doi: 10.1038/srep33073
   PubMedGoogle Scholar
• Zhang Q, Lu P, Zhang J. Correlation of serum lipoprotein-associated phosphatase A2 with vascular dementia due to ischemic stroke. Natl Med J China. 2018;98(15):1171–1175. doi: 10.3760/cma.j.issn.0376-2491.2018.15.010
   Google Scholar
• Zhu S, Wei X, Yang X, et al. Plasma lipoprotein-associated phospholipase A2 and superoxide dismutase are independent predicators of cognitive impairment in cerebral small vessel disease patients: diagnosis and assessment. Aging Dis. 2019 Aug;10(4):834–846. doi: 10.14336/AD.2019.0304
   PubMed Web of Science ®Google Scholar
• van Himbergen TM, Beiser AS, Ai M, et al. Biomarkers for insulin resistance and inflammation and the risk for all-cause dementia and Alzheimer disease: results from the Framingham heart study. Arch Neurol. 2012 May;69(5):594–600. doi: 10.1001/archneurol.2011.670
   PubMedGoogle Scholar
• Huang F, Wang K, Shen J. Lipoprotein-associated phospholipase A2: the story continues. Med Res Rev. 2020 Jan;40(1):79–134. doi: 10.1002/med.21597
   PubMed Web of Science ®Google Scholar
• Irwin MR, Vitiello MV. Implications of sleep disturbance and inflammation for Alzheimer’s disease dementia. Lancet Neurol. 2019 Mar;18(3):296–306. doi: 10.1016/S1474-4422(18)30450-2
   PubMed Web of Science ®Google Scholar
• Marsland AL, Gianaros PJ, Kuan DC, et al. Brain morphology links systemic inflammation to cognitive function in midlife adults. Brain Behav Immun. 2015 Aug;48:195–204. doi: 10.1016/j.bbi.2015.03.015
   PubMed Web of Science ®Google Scholar
• Bradburn S, Murgatroyd C, Ray N. Neuroinflammation in mild cognitive impairment and Alzheimer’s disease: a meta-analysis. Ageing Res Rev. 2019 Mar;50:1–8. doi: 10.1016/j.arr.2019.01.002
   PubMed Web of Science ®Google Scholar
• Blevins BL, Vinters HV, Love S, et al. Brain arteriolosclerosis. Acta Neuropathol. 2021 Jan;141(1):1–24. doi: 10.1007/s00401-020-02235-6
   PubMed Web of Science ®Google Scholar
• Wang Z, Chen WH, Li SX, et al. Gut microbiota modulates the inflammatory response and cognitive impairment induced by sleep deprivation. Mol Psychiatry. 2021 Nov;26(11):6277–6292. doi: 10.1038/s41380-021-01113-1
   PubMed Web of Science ®Google Scholar
• Simonetto M, Infante M, Sacco RL, et al. A novel anti-inflammatory role of omega-3 PUFAs in prevention and treatment of atherosclerosis and vascular cognitive impairment and dementia. Nutrients. 2019 Sep 23;11(10):2279. doi: 10.3390/nu11102279
   PubMed Web of Science ®Google Scholar
• Nation DA, Sweeney MD, Montagne A, et al. Blood-brain barrier breakdown is an early biomarker of human cognitive dysfunction. Nat Med. 2019 Feb;25(2):270–276. doi: 10.1038/s41591-018-0297-y
   PubMed Web of Science ®Google Scholar